

Paul M. Rivard discusses the Myriad case in the San Francisco Daily Journal, Thomson Reuters, BioWorld Today, Boston Business Journal, Managing Intellectual Property and Chemical & Engineering News

April 17, 2013

Mr. Rivard discusses the Supreme Court's oral argument in *Association for Molecular Pathology et al. v. Myriad Genetics Inc. et al.* in a *San Francisco Daily Journal* article titled, "[Human gene patents, biotech industry face Supreme Court scrutiny](#)" (subscription required).

He also discusses the case and its implications in a *Thomson Reuters* article titled, "[Justices appear to take middle ground on human gene patents](#)," a *BioWorld Today* article titled, "[Supreme Court Grapples With Science of DNA Claims](#)" (subscription required), a *Boston Business Journal* article titled, "[Patent attorney predicts middle path in Myriad decision](#)," a *Managing Intellectual Property* article titled, "[Reading the tea leaves from Myriad](#)" (subscription required), and a *Chemical & Engineering News* article titled, "[Court Reviews Genetic Patents](#)."

Posted: April 12, 2013